Advertisement
UK markets close in 1 hour 6 minutes
  • FTSE 100

    8,131.88
    -12.25 (-0.15%)
     
  • FTSE 250

    19,924.75
    -40.64 (-0.20%)
     
  • AIM

    764.93
    +4.19 (+0.55%)
     
  • GBP/EUR

    1.1686
    -0.0022 (-0.19%)
     
  • GBP/USD

    1.2485
    -0.0011 (-0.09%)
     
  • Bitcoin GBP

    45,920.57
    -2,754.24 (-5.66%)
     
  • CMC Crypto 200

    1,196.34
    -142.73 (-10.66%)
     
  • S&P 500

    5,019.10
    -16.59 (-0.33%)
     
  • DOW

    37,863.76
    +47.84 (+0.13%)
     
  • CRUDE OIL

    81.16
    -0.77 (-0.94%)
     
  • GOLD FUTURES

    2,320.50
    +17.60 (+0.76%)
     
  • NIKKEI 225

    38,274.05
    -131.61 (-0.34%)
     
  • HANG SENG

    17,763.03
    +16.12 (+0.09%)
     
  • DAX

    17,932.17
    -186.15 (-1.03%)
     
  • CAC 40

    7,984.93
    -80.22 (-0.99%)
     

OptiNose (NASDAQ:OPTN) shareholders have endured a 87% loss from investing in the stock five years ago

OptiNose, Inc. (NASDAQ:OPTN) shareholders should be happy to see the share price up 13% in the last quarter. But will that repair the damage for the weary investors who have owned this stock as it declined over half a decade? Probably not. In fact, the share price has tumbled down a mountain to land 87% lower after that period. So we don't gain too much confidence from the recent recovery. The important question is if the business itself justifies a higher share price in the long term. We really feel for shareholders in this scenario. It's a good reminder of the importance of diversification, and it's worth keeping in mind there's more to life than money, anyway.

With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies.

Check out our latest analysis for OptiNose

OptiNose wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

ADVERTISEMENT

Over five years, OptiNose grew its revenue at 27% per year. That's better than most loss-making companies. So on the face of it we're really surprised to see the share price has averaged a fall of 13% each year, in the same time period. It could be that the stock was over-hyped before. While there might be an opportunity here, you'd want to take a close look at the balance sheet strength.

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

earnings-and-revenue-growth
earnings-and-revenue-growth

You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.

A Different Perspective

While the broader market gained around 28% in the last year, OptiNose shareholders lost 29%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, longer term shareholders are suffering worse, given the loss of 13% doled out over the last five years. We would want clear information suggesting the company will grow, before taking the view that the share price will stabilize. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. To that end, you should learn about the 2 warning signs we've spotted with OptiNose (including 1 which is concerning) .

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.